Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

BACKGROUND: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitors are routinely used as adjuvant and first-line t...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Thoracic tumor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360149/
https://www.ncbi.nlm.nih.gov/pubmed/30847464
http://dx.doi.org/10.1093/annonc/mdz077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360149/
https://www.ncbi.nlm.nih.gov/pubmed/30847464
http://dx.doi.org/10.1093/annonc/mdz077

Ejemplares similares